ZNF397 Knockout cell line (K-562)

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

ZNF397 (zinc finger protein 397) encodes a zinc finger protein containing an N-terminal SCAN domain and C2H2-type zinc finger repeats. The protein localizes to centromeres during interphase and early prophase and has been shown to either repress or activate transcription depending on the context. These properties suggest roles in chromosome-associated processes and transcriptional regulation, although the specific molecular mechanisms and physiological functions of ZNF397 remain incompletely defined.

The K-562 cell line was established by Lozzio and Lozzio in 1970 from the pleural effusion of a 53-year-old female patient with chronic myeloid leukemia (CML) in blast crisis. The cells carry the BCR-ABL1 e14-a2 (b3-a2) fusion gene and exhibit characteristics of myeloid leukemia cells, including hemoglobin production. K-562 is a human leukemia cell model widely used for studying CML biology, myeloid differentiation, hematopoietic signaling, and immune cell interactions, including applications as an in vitro target model in natural killer (NK) cell assays.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.